||
全面、准确认识,了解科技文献信息,十分重要。
科研人员从文献数据库检索到的相关文献,应该看文章的题目、作者、作者单位、文摘、关键词、相似文献、被引文献、参考文献、文献主题词、化学物质词汇、相关信息资源、科研资助信息、更多信息资源链接、全文获取信息。
还有文献类型,包括图书与文献、临床试验、MATA分析、随机对照试验、综述、系统综述,
等等
实例 两个 可以看看
https://pubmed.ncbi.nlm.nih.gov/36308626/
https://pubmed.ncbi.nlm.nih.gov/?term=%22Autophagy%2Fgenetics%22%5BMeSH%5D&sort=date&sort_order=desc
Cell Mol Life Sci
. 2022 Oct 29;79(11):573.
doi: 10.1007/s00018-022-04595-6.
Affiliations expand
PMID: 36308626
Mitochondrial dynamics are balanced fission and fusion events that regulate mitochondrial morphology, and alteration in these events results in mitochondrial dysfunction and contributes to many diseases, including tumorigenesis. Ovarian cancer (OC) cells exhibit fragmented mitochondria, but the mechanism by which mitochondrial dynamics regulators contribute to OC is considerably less clear. Here, we elucidated the potential role of Mfn2-mediated mitochondrial fusion in OC and present evidence that genetic or pharmacological activation of Mfn2 leads to mitochondrial fusion and reduces ROS generation, which correlates with reduced cell proliferation, invasion, migration, and EMT in OC cells. Also, increased mitochondrial fusion promotes the F-actin remodeling, reduces lamellipodia formation, and thus reduces EMT. Increased expression of Mfn2 triggers AMPK, promotes autophagy, reduces ROS, and suppresses OC progression by downregulating the p-mTOR (2481 and 2448) and p-ERK axis. OC patients with higher Mfn2 expression have better survival than those with lower Mfn2 levels. Our findings demonstrate that restoration of Mfn2-mediated mitochondrial fusion suppressed OC progression and suggest that this process could be a potential strategy in OC treatment.
Keywords: AMPK; Autophagy; EMT; Mfn2; Ovarian cancer; ROS.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Ovarian Cancer: A Landscape of Mitochondria with Emphasis on Mitochondrial Dynamics.
Int J Mol Sci. 2023 Jan 8;24(2):1224. doi: 10.3390/ijms24021224.PMID: 36674740 Free PMC article. Review.
Oxid Med Cell Longev. 2018 Jun 26;2018:2798070. doi: 10.1155/2018/2798070. eCollection 2018.PMID: 30046371 Free PMC article.
Biochim Biophys Acta. 2014 Feb;1842(2):220-31. doi: 10.1016/j.bbadis.2013.11.009. Epub 2013 Nov 16.PMID: 24252614 Free PMC article.
Cell Death Dis. 2018 May 1;9(5):515. doi: 10.1038/s41419-018-0552-7.PMID: 29725013 Free PMC article.
Mitochondrial activity and dynamics changes regarding metabolism in ageing and obesity.
Mech Ageing Dev. 2017 Mar;162:108-121. doi: 10.1016/j.mad.2016.12.005. Epub 2016 Dec 16.PMID: 27993601 Review.
Ovarian Cancer: A Landscape of Mitochondria with Emphasis on Mitochondrial Dynamics.
Int J Mol Sci. 2023 Jan 8;24(2):1224. doi: 10.3390/ijms24021224.PMID: 36674740 Free PMC article. Review.
J Transl Med. 2023 Jan 16;21(1):27. doi: 10.1186/s12967-023-03878-1.PMID: 36647167 Free PMC article. Review.
Virol J. 2022 Dec 31;19(1):228. doi: 10.1186/s12985-022-01932-w.PMID: 36587218 Free PMC article.
Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer. Evolution of management in the era of precision medicine. CA Cancer J Clin 69:280–304. https://doi.org/10.3322/caac.21559 - DOI - PubMed
Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708 - DOI - PubMed
Howlader N, Noone AM, Krapcho M, Miller D, Brest A Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER Cancer Statistics Review, National Cancer Institute, Bethesda, MD (1975–2017). https://seer.cancer.gov/csr/1975_2017/ based on November 2019 SEER data submission, posted to the SEER web site, April 2020
Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, DeGeest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419–1425. https://doi.org/10.1200/JCO.2008.19.1684 - DOI - PubMed - PMC
du Bois A, Lück H-J, Meier W, Adams H-P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1329. https://doi.org/10.1093/jnci/djg036 - DOI - PubMed
Show all 63 references
AMP-Activated Protein Kinases / genetics
Autophagy / genetics
Female
GTP Phosphohydrolases / genetics
GTP Phosphohydrolases / metabolism
Humans
Mitochondrial Dynamics* / genetics
Mitochondrial Proteins / genetics
Mitochondrial Proteins / metabolism
Ovarian Neoplasms* / genetics
Reactive Oxygen Species / metabolism
TOR Serine-Threonine Kinases / genetics
Reactive Oxygen Species
GTP Phosphohydrolases
AMP-Activated Protein Kinases
Mitochondrial Proteins
TOR Serine-Threonine Kinases
MFN2 protein, human
MTOR protein, human
https://pubmed.ncbi.nlm.nih.gov/?term=%22Autophagy%2Fgenetics%22%5BMeSH%5D&sort=date&sort_order=desc
text availability
Abstract
Free full text
Full text
article attribute
Associated data
article type
Books and Documents
Clinical Trial
Meta-Analysis
Randomized Controlled Trial
Review
Systematic Review
publication date
1 year
5 years
10 years
Custom Range
Additional filters Reset all filters
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-12-27 23:11
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社